Crosstalk of the Androgen Receptor with Transcriptional Collaborators: Potential Therapeutic Targets for Castration-Resistant Prostate Cancer
Prostate cancer is the second leading cause of death from cancer among males in Western countries. It is also the most commonly diagnosed male cancer in Japan. The progression of prostate cancer is mainly influenced by androgens and the androgen receptor (AR). Androgen deprivation therapy is an esta...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2017-02-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2072-6694/9/3/22 |
| _version_ | 1797712960190152704 |
|---|---|
| author | Daisuke Obinata Kenichi Takayama Satoru Takahashi Satoshi Inoue |
| author_facet | Daisuke Obinata Kenichi Takayama Satoru Takahashi Satoshi Inoue |
| author_sort | Daisuke Obinata |
| collection | DOAJ |
| description | Prostate cancer is the second leading cause of death from cancer among males in Western countries. It is also the most commonly diagnosed male cancer in Japan. The progression of prostate cancer is mainly influenced by androgens and the androgen receptor (AR). Androgen deprivation therapy is an established therapy for advanced prostate cancer; however, prostate cancers frequently develop resistance to low testosterone levels and progress to the fatal stage called castration-resistant prostate cancer (CRPC). Surprisingly, AR and the AR signaling pathway are still activated in most CRPC cases. To overcome this problem, abiraterone acetate and enzalutamide were introduced for the treatment of CRPC. Despite the impact of these drugs on prolonged survival, CRPC acquires further resistance to keep the AR pathway activated. Functional molecular studies have shown that some of the AR collaborative transcription factors (TFs), including octamer transcription factor (OCT1), GATA binding protein 2 (GATA2) and forkhead box A1 (FOXA1), still stimulate AR activity in the castration-resistant state. Therefore, elucidating the crosstalk between the AR and collaborative TFs on the AR pathway is critical for developing new strategies for the treatment of CRPC. Recently, many compounds targeting this pathway have been developed for treating CRPC. In this review, we summarize the AR signaling pathway in terms of AR collaborators and focus on pyrrole-imidazole (PI) polyamide as a candidate compound for the treatment of prostate cancer. |
| first_indexed | 2024-03-12T07:28:31Z |
| format | Article |
| id | doaj.art-b1d85e9901b745229a7d6d2f0c7bf784 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-12T07:28:31Z |
| publishDate | 2017-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-b1d85e9901b745229a7d6d2f0c7bf7842023-09-02T21:57:26ZengMDPI AGCancers2072-66942017-02-01932210.3390/cancers9030022cancers9030022Crosstalk of the Androgen Receptor with Transcriptional Collaborators: Potential Therapeutic Targets for Castration-Resistant Prostate CancerDaisuke Obinata0Kenichi Takayama1Satoru Takahashi2Satoshi Inoue3Department of Urology, Nihon University School of Medicine, Tokyo 173-8610, JapanDepartment of Functional Biogerontology, Tokyo Metropolitan Institute of Gerontology, Tokyo 173-0015, JapanDepartment of Urology, Nihon University School of Medicine, Tokyo 173-8610, JapanDepartment of Functional Biogerontology, Tokyo Metropolitan Institute of Gerontology, Tokyo 173-0015, JapanProstate cancer is the second leading cause of death from cancer among males in Western countries. It is also the most commonly diagnosed male cancer in Japan. The progression of prostate cancer is mainly influenced by androgens and the androgen receptor (AR). Androgen deprivation therapy is an established therapy for advanced prostate cancer; however, prostate cancers frequently develop resistance to low testosterone levels and progress to the fatal stage called castration-resistant prostate cancer (CRPC). Surprisingly, AR and the AR signaling pathway are still activated in most CRPC cases. To overcome this problem, abiraterone acetate and enzalutamide were introduced for the treatment of CRPC. Despite the impact of these drugs on prolonged survival, CRPC acquires further resistance to keep the AR pathway activated. Functional molecular studies have shown that some of the AR collaborative transcription factors (TFs), including octamer transcription factor (OCT1), GATA binding protein 2 (GATA2) and forkhead box A1 (FOXA1), still stimulate AR activity in the castration-resistant state. Therefore, elucidating the crosstalk between the AR and collaborative TFs on the AR pathway is critical for developing new strategies for the treatment of CRPC. Recently, many compounds targeting this pathway have been developed for treating CRPC. In this review, we summarize the AR signaling pathway in terms of AR collaborators and focus on pyrrole-imidazole (PI) polyamide as a candidate compound for the treatment of prostate cancer.http://www.mdpi.com/2072-6694/9/3/22androgen receptorandrogen receptor signaling pathwaycoregulatoroctamer transcription factor 1pyrrole-imidazole polyamide |
| spellingShingle | Daisuke Obinata Kenichi Takayama Satoru Takahashi Satoshi Inoue Crosstalk of the Androgen Receptor with Transcriptional Collaborators: Potential Therapeutic Targets for Castration-Resistant Prostate Cancer Cancers androgen receptor androgen receptor signaling pathway coregulator octamer transcription factor 1 pyrrole-imidazole polyamide |
| title | Crosstalk of the Androgen Receptor with Transcriptional Collaborators: Potential Therapeutic Targets for Castration-Resistant Prostate Cancer |
| title_full | Crosstalk of the Androgen Receptor with Transcriptional Collaborators: Potential Therapeutic Targets for Castration-Resistant Prostate Cancer |
| title_fullStr | Crosstalk of the Androgen Receptor with Transcriptional Collaborators: Potential Therapeutic Targets for Castration-Resistant Prostate Cancer |
| title_full_unstemmed | Crosstalk of the Androgen Receptor with Transcriptional Collaborators: Potential Therapeutic Targets for Castration-Resistant Prostate Cancer |
| title_short | Crosstalk of the Androgen Receptor with Transcriptional Collaborators: Potential Therapeutic Targets for Castration-Resistant Prostate Cancer |
| title_sort | crosstalk of the androgen receptor with transcriptional collaborators potential therapeutic targets for castration resistant prostate cancer |
| topic | androgen receptor androgen receptor signaling pathway coregulator octamer transcription factor 1 pyrrole-imidazole polyamide |
| url | http://www.mdpi.com/2072-6694/9/3/22 |
| work_keys_str_mv | AT daisukeobinata crosstalkoftheandrogenreceptorwithtranscriptionalcollaboratorspotentialtherapeutictargetsforcastrationresistantprostatecancer AT kenichitakayama crosstalkoftheandrogenreceptorwithtranscriptionalcollaboratorspotentialtherapeutictargetsforcastrationresistantprostatecancer AT satorutakahashi crosstalkoftheandrogenreceptorwithtranscriptionalcollaboratorspotentialtherapeutictargetsforcastrationresistantprostatecancer AT satoshiinoue crosstalkoftheandrogenreceptorwithtranscriptionalcollaboratorspotentialtherapeutictargetsforcastrationresistantprostatecancer |